



**FOR IMMEDIATE RELEASE**

## **Compugen to Present at Jefferies 2015 Global Healthcare Conference in London**

Tel Aviv, Israel - November 12, 2015 – Compugen Ltd. ([NASDAQ: CGEN](#)), a leading predictive drug discovery company, today announced that Dr. Anat Cohen-Dayag, President and Chief Executive Officer of Compugen, will present a corporate overview and update at the Jefferies 2015 Global Healthcare Conference in London, UK, on Wednesday, November 18, 2015.

### **About Compugen**

Compugen is a leading drug discovery company utilizing its broadly applicable predictive discovery infrastructure to identify novel drug targets and develop first-in-class biologics. The Company's current pipeline primary focus is on immune checkpoint target candidates discovered by the Company, potentially providing the basis for a next wave of therapeutics for cancer immunotherapy. Compugen's business model is based on selectively entering into collaborations for its novel targets and drug product candidates at various stages of research and development under revenue-sharing agreements. The Company is headquartered in Tel Aviv, Israel, with R&D facilities in Tel Aviv and South San Francisco. At the US facilities, monoclonal antibody therapeutic candidates are discovered and developed against the Company's novel target candidates. For additional information, please visit Compugen's corporate website at [www.cgen.com](http://www.cgen.com).

### **Company contact:**

Tsipi Haitovsky  
Global Media Liaison  
Compugen Ltd.  
Email: [tsipih@cgen.com](mailto:tsipih@cgen.com)  
Tel: +972-52-598-9892